Clinical Trials Browser

NETWORK × Breast Neoplasms × durvalumab × Clear all

NCT02649686 2023-08-04

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Phase 1 Completed

Breast Neoplasms